Identifying high-risk myeloma and improving treatment strategies in these patients

Multiple myeloma is a heterogeneous disease, and despite recent advances in therapeutic agents, several patients still relapse after therapy and…

Date: 22nd September 2022

Improving the efficiency of drug approvals in MDS

In recent years, the treatment and management of myelodysplastic syndromes (MDS) has improved, and several clinical trials are investigating novel…

Date: 14th September 2022

Identifying high-risk myeloma and improving treatment strategies in these patients

Multiple myeloma is a heterogeneous disease, and despite recent advances in therapeutic agents, several patients still relapse after therapy and…

Date: 22nd September 2022

Improving the efficiency of drug approvals in MDS

In recent years, the treatment and management of myelodysplastic syndromes (MDS) has improved, and several clinical trials are investigating novel…

Date: 14th September 2022

Highlights from the 2022 Texas MPN Workshop: advances in MPN treatment

Myeloproliferative neoplasms (MPNs) represent a group of rare and heterogeneous diseases which remain a challenge to treat. Several advances have…

Date: 9th September 2022

The need for more effective first-line therapies in MDS

The treatment and management of myelodysplastic syndromes (MDS) remains a challenge due to the heterogeneity of the disease, and early…

Date: 7th September 2022

Myeloma 2022: day two highlights

There were several fascinating sessions and discussions at the Myeloma 2022 meeting that took place in Scottsdale, AZ. Topics that…

Date: 2nd September 2022

The promise of CAR-T therapy in CLL and challenges in the field

The treatment landscape of chronic lymphocytic leukemia (CLL) has greatly transformed over the years with the introduction of several agents,…

Date: 31st August 2022

Clonal hematopoiesis and pre-MDS states

The relationship between mutations and precursor states in myelodysplastic syndromes (MDS) is a growing area of research, and advances in…

Date: 24th August 2022

T-cell engagers in multiple myeloma: current challenges and future outlooks

Several novel agents have been approved in the field of multiple myeloma and have greatly transformed the treatment landscape of…

Date: 24th August 2022

High-risk MDS: unmet needs and future treatment approaches

Myelodysplastic syndromes (MDS) represent a heterogeneous group of myeloid neoplasms, and the treatment and management of high-risk MDS remains a…

Date: 19th August 2022

The importance of patient-reported outcomes in CAR-T recipients

CAR-T therapies have been approved for use in several hematological malignancies, and have greatly improved treatment options for patients, especially…

Date: 17th August 2022

CAR-T therapy in myeloma and lymphoma

CAR-T therapy has revolutionized the treatment landscape of several hematological malignancies, and ongoing clinical trials continue to provide valuable data…

Date: 12th August 2022

CAR-T therapy in AML: challenges and future outlooks

Acute myeloid leukemia (AML) is an aggressive and heterogeneous hematological malignancy that poses many challenges for diagnosis and treatment. While…

Date: 10th August 2022

The current state of CAR-T therapy in lymphoma

Over the last few decades, advances in immunotherapies including CAR-T therapy have revolutionized the treatment of patients with relapsed/refractory (R/R)…

Date: 5th August 2022

Myeloma treatment updates from EHA 2022

While multiple myeloma remains a challenging disease to treat, there have been several advances in the field over the years….

Date: 3rd August 2022

Updates in classification and risk stratification in MDS

Classification and risk stratification are crucial for the management and treatment of patients with myelodysplastic syndromes (MDS). For many years,…

Date: 27th July 2022

Myeloma 2022: day one highlights

At the Myeloma 2022 meeting held in Scottsdale, AZ, there were several fascinating sessions that took place covering a variety…

Date: 27th July 2022

Immune dysregulation and targeting in MDS

Myelodysplastic syndromes (MDS) are a type of rare and heterogeneous hematological malignancy, and immune dysregulation plays a major role in…

Date: 22nd July 2022

The future of CAR-T therapy in ALL

Acute lymphoblastic leukemia (ALL) is an aggressive and heterogeneous disease with a high mortality rate. However, several advances have been…

Date: 20th July 2022

An insight into novel targets in myeloma and mechanisms of resistance to PIs and IMiDs

Multiple myeloma has seen many advances in recent years, and novel targeted agents are transforming the field. Several immunotherapies, including…

Date: 15th July 2022

Key updates in the treatment and management of MPNs

Myeloproliferative neoplasms (MPNs) are a class of hematological cancers characterized by the excessive production of a particular blood cell. MPNs…

Date: 8th July 2022

Addressing unmet needs and future treatment approaches in AL amyloidosis

Amyloidosis is a heterogeneous disease that results from the deposition of abnormal protein aggregates in various tissues and organs. The…

Date: 1st July 2022

Myeloma treatment in the UK: updates from Muk Nine b: OPTIMUM & the importance of genomics

While the treatment of multiple myeloma has seen several recent advances, challenges still remain when approaching patients with high-risk disease,…

Date: 24th June 2022

Updates in lymphoma and CLL treatment in the UK

In recent years, there have been many advances in the treatment of lymphoma and chronic lymphocytic leukemia (CLL) in the…

Date: 17th June 2022

The importance of early interception and intervention in myeloma

Multiple myeloma is a heterogenous and complex disease, with many experts agreeing that screening for precursor conditions can improve patient…

Date: 7th June 2022

Impact of the COVID-19 pandemic on the EBMT & projects in the pipeline

The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), which took place on 19-23 March…

Date: 3rd June 2022

CAR-T and lymphoma treatment in the UK

Lymphoma treatment has seen many recent advances, with CAR-T therapy being a game changer for patients. Several clinical trials investigating…

Date: 27th May 2022

Harnessing the power of immunotherapy in myeloma and amyloidosis

The myeloma treatment landscape has seen a lot of progress in the last few years, with several novel therapies emerging,…

Date: 20th May 2022

The impact of AI and machine learning algorithms in MDS

Artificial intelligence (AI) and machine learning algorithms are transforming treatment and prognosis in hematological malignancies, as well as other areas…

Date: 13th May 2022

MMRF-CoMMpass: the genomic basis of myeloma subtypes

Despite significant advances in molecular profiling and treatments for multiple myeloma, patients with high-risk and ultra high-risk disease still have…

Date: 6th May 2022

Genomics in the age of immuno-oncology

Immunotherapies are at the forefront of myeloma treatment and there are many questions remaining. Defining high-risk is important when making…

Date: 29th April 2022

Understanding multiple myeloma at the single-cell level

Relapsed/refractory (R/R) multiple myeloma remains an incurable hematological malignancy with an unmet clinical need.  It is necessary to gain a…

Date: 22nd April 2022

Recent advances in amyloidosis treatment

Amyloidosis is a disease that results from the accumulation of a toxic, insoluble protein called amyloid in various tissues and…

Date: 1st April 2022

ASH 2021: a deep dive into ALL immunotherapy

Various forms of immunotherapy represent a novel treatment option, especially for patients who progress from conventional chemotherapy hematopoietic stem-cell transplantation…

Date: 25th March 2022

ASH 2021: what did ASH 2021 mean for MDS?

With high rates of relapse in patients with myelodysplastic syndromes (MDS), there is a great unmet need for novel treatments…

Date: 18th March 2022

ASH 2021: novel developments in MPNs

The JAK-STAT pathway plays a pivotal role in the pathogenesis of myeloproliferative neoplasms (MPNs) including polycythemia vera, essential thrombocythemia, and…

Date: 11th March 2022

ASH 2021: evaluating the impact of screening for MGUS and SMM

Multiple myeloma is always preceded by two precursor conditions known as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple…

Date: 4th March 2022

ASH 2021: the future of cell therapies in lymphoma

Cell therapies including chimeric antigen receptor (CAR) T-cell therapy represent novel treatments for patients with lymphoma, especially for those who…

Date: 25th February 2022

ASH 2021: highlights in CLL clinical trials

Treatments such as ibrutinib and venetoclax, which target the Bruton tyrosine kinase (BTK) pathway and the B-cell lymphoma 2 (BCL-2)…

Date: 18th February 2022

ASH 2021: updates in FLT3 mutated AML

FMS-like tyrosine kinase 3 (FLT3) mutations are common in patients with acute myeloid leukemia (AML), and is often associated with…

Date: 11th February 2022

The Lymphoma Sessions: post-ASH 2021

The 63rd American Society of Hematology (ASH) annual meeting saw a plethora of updates in lymphoma. While most of them…

Date: 2nd February 2022

COSTEM: maintenance therapies for FLT3+ AML

The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in approximately 30% of patients with acute myeloid leukemia (AML) and…

Date: 25th October 2021

COSTEM: the role of alloHSCT in ALL

Over the past few years, the therapeutic landscape for acute lymphoblastic leukemia (ALL) has dramatically evolved, with the development of…

Date: 25th October 2021

SOHO 2021: amyloidosis treatment updates

Over the last two decades the outcomes of patients with amyloidosis have substantially improved with timely diagnosis, the use of…

Date: 30th September 2021

IACH 2021: CAR-T in clinical practice

Currently, five chimeric antigen receptor T-cell (CAR-T) therapies are approved for the treatment of hematological malignancies including acute lymphoblastic leukemia,…

Date: 30th September 2021

Unmet needs and recent updates in CML

The treatment of chronic myeloid leukemia (CML) has substantially evolved since the FDA approval of the tyrosine kinase inhibitor imatinib…

Date: 29th September 2021

IMW 2021: treatment-free intervals in multiple myeloma

Continuous therapy has been a key aspect of the standard of care approaches for the treatment of multiple myeloma for…

Date: 29th September 2021

Highlights from iwCLL 2021

The management of chronic lymphocytic leukemia (CLL) has evolved drastically over the last few years, with the introduction of novel…

Date: 27th September 2021

IMW 2021: MRD in myeloma

Measurable residual disease (MRD) is emerging as an important prognostic marker in the management of multiple myeloma. Promising clinical evidence…

Date: 20th September 2021

CAR-T vs bispecifics: replacing ASCT in myeloma

Autologous stem cell transplantation (ASCT) has been the standard of care patients with multiple myeloma for the past three decades;…

Date: 17th September 2021

EHA 2021: antibody therapies for NHL

Antibody therapies are rapidly transforming the treatment landscape of non-Hodgkin lymphoma (NHL). Since the development of rituximab as an anti-CD20…

Date: 10th September 2021

EHA 2021: updates on novel agents for AML

A significant number of patients with acute myeloid leukemia (AML) are unable to withstand intensive chemotherapy regimens due to older…

Date: 8th September 2021

Texas MPN Workshop 2021: updates on JAK inhibitors for MPNs

Janus kinase (JAK) inhibitors are becoming an increasingly prominent class of drug in the treatment of myeloproliferative neoplasms (MPNs), in…

Date: 3rd September 2021

EHA 2021: targeted therapies for ALL

Great progress has been made in the treatment of acute lymphocytic leukemia (ALL), primarily owing to the development of targeted…

Date: 1st September 2021

Texas MPN Workshop 2021: updates on interferons for MPNs

Many clinical trials are currently investigating the potential benefits of interferons in the treatment of myeloproliferative neoplasms (MPNs), in particular…

Date: 27th August 2021

EHA 2021: real-world data on myeloma, lymphoma and CLL

Real-world data gained through scientific studies is essential in the advancement of treatments for all hematological malignancies. Historically, pharmaceutical companies…

Date: 25th August 2021

Novel BTK inhibitors for NHL

Over the past two decades the treatment landscape for non-Hodgkin lymphoma (NHL) has rapidly evolved, with the development of Bruton’s…

Date: 19th August 2021

Latest updates on T-cell therapies for non-Hodgkin lymphoma

Research into the treatment of non-Hodgkin lymphoma (NHL) has made great progress within the last decade, with clinical trials such…

Date: 18th August 2021

Novel CD20/CD3 bispecific antibodies in NHL

Immunotherapies are showing increasingly promising results for the treatment of patients with non-Hodgkin lymphoma (NHL) and, in particular, bispecific antibodies…

Date: 17th August 2021

Latest updates on CAR-T therapy for lymphoma

At present, four types of chimeric antigen receptor T-cell (CAR-T) therapy are FDA approved for specific types of lymphoma: for…

Date: 16th August 2021

EHA & ICML 2021: updates in Hodgkin lymphoma

Although classical Hodgkin lymphoma has a high cure and overall survival rate, the treatment of relapsed/refractory disease, treatment-related adverse events,…

Date: 6th August 2021

Latest transplant updates from EHA 2021

Hematopoietic stem cell transplantation (HSCT) is used as a treatment option for a wide variety of hematological disorders. Graft-versus-host disease…

Date: 4th August 2021

Key updates on CAR-T therapy for multiple myeloma

The treatment of multiple myeloma is a rapidly evolving field with advances in the understanding of myeloma disease biology contributing…

Date: 2nd August 2021

The Lymphoma Sessions: highlights from EHA and ICML 2021

In this roundtable discussion, chaired by Gilles Salles, MD, PhD, Memorial Sloan Kettering, New York, NY; Nirav N. Shah, MD,…

Date: 30th July 2021

The CLL Sessions: highlights from EHA and ICML 2021

In this roundtable discussion, chaired by Paolo Ghia, MD, PhD, Università Vita-Salute San Raffaele, Milan, Italy; Susan O’Brien, MD, University…

Date: 27th July 2021

EHA 2021: updates on treatment for MDS

Myelodysplastic syndromes (MDS) are a group of myeloid clonal disorders caused by a defect in bone marrow, which hinders their…

Date: 26th July 2021

iwNHL 2021: immunotherapy and the microenvironment

Recent progress in the field of immunotherapy presents an exciting alternative to standard chemotherapy treatments for patients with non-Hodgkin lymphoma….

Date: 23rd July 2021

The Myeloma Sessions: key highlights from EHA and ASCO 2021

The introduction of many novel drug classes and therapies has resulted in significant improvements in overall survival outcomes for patients…

Date: 21st July 2021

EHA 2021: key trial updates in myelofibrosis

The breakthrough discovery of upregulation of the JAK-STAT signaling pathway as the driving force behind myeloproliferative neoplasms (MPNs) has led…

Date: 20th July 2021

The MPN Sessions: highlights from EHA and ASCO 2021

Over the past decade there has been a vast increase in the number of clinical trials taking place in the…

Date: 16th July 2021

The MDS Sessions: highlights from ASCO/EHA 2021

Treatment options for patients with myelodysplastic syndromes (MDS) remain limited, with the rapid advances seen in other hematological malignancies not…

Date: 8th July 2021

EHA 2021: fixed-duration therapies and sequencing in CLL

Over the last years, the chronic lymphocytic leukemia (CLL) field has seen significant growth in new drugs and new treatment…

Date: 8th July 2021

The AML Sessions: Highlights from ASCO/EHA 2021

Acute myeloid leukemia (AML) is a clonal hematologic malignancy defined by genetic heterogeneity due to recurrent gene mutations. Precision medicine…

Date: 7th July 2021

EHA 2021: key trial updates in myeloma

The treatment and management of multiple myeloma has evolved drastically over the last ten years with the introduction of many…

Date: 7th July 2021

Key updates on CAR-T therapy for ALL

There are several forms of acute lymphoblastic leukemia (ALL), with B-cell ALL being the most common (around 75% of cases)….

Date: 5th July 2021

The Myeloma Sessions: post-COMy 2021 myeloma patients session

During the COVID-19 pandemic, myeloma support and advocacy groups were forced to adapt to a new way of working in…

Date: 28th June 2021

EHA 2021: MRD in myeloma

Over the past ten years, the approval of several new and effective therapies for multiple myeloma has significantly improved overall…

Date: 25th June 2021

Latest updates on CAR-T therapy for CLL

Chronic lymphocytic leukemia (CLL) is slow to develop and can be hard to treat as patients relapse or become refractory…

Date: 16th June 2021

The Myeloma Sessions: post-COMy 2021 roundtable

Age is an important prognostic factor in multiple myeloma, with patients aged over 75 years showing inferior outcomes when compared…

Date: 3rd June 2021

Focus on ALL: treating older patients, Ph-like ALL & post-transplant interventions

Advances in both the treatment landscape and the pathology of the disease have improved the outcome of children and adults…

Date: 28th May 2021

MDS Session: Women in Science

Myelodysplastic syndromes (MDS) are a heterogenous group of myeloid disorders characterized by the accumulation of dysplastic cells within the bone…

Date: 17th May 2021

Key updates on CAR-T & cellular therapy for AML

Acute myeloid leukemia (AML) is the most common type of leukemia in adults and is highly heterogenous. AML is typically…

Date: 17th May 2021

The MDS Sessions: highlights from ASH 2020

Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterized by the accumulation of dysplastic cells within the bone…

Date: 27th April 2021

The Transplant Sessions: ASH 2020 highlights

The management of post-transplantation relapse and immune attack is an ongoing battle in patients undergoing bone marrow transplants. The efficacy…

Date: 23rd April 2021

The Lymphoma Sessions: ASH 2020 highlights

The treatment of aggressive lymphomas such as diffuse large B-cell has seen dramatic changes, and with the advent of bispecific…

Date: 23rd April 2021

Latest updates in Hodgkin lymphoma from ISHL HL 2021

The International Symposium on Hodgkin Lymphoma (ISHL) 2021 Hodgkin Lymphoma (HL) update gathered an international panel to discuss the most…

Date: 20th April 2021

The Myeloma Sessions: Post-ASH 2020 UK Discussion

The development of immunomodulatory agents and proteasome inhibitors alongside stem cell transplantation and chemotherapy has significantly improved the treatment options…

Date: 19th April 2021

The Post-EBMT for Trainees VJSessions

The European Group for Blood and Marrow Transplantation (EBMT) Trainee Committee was established in 2021 to address the needs of…

Date: 15th April 2021

Post-ASH Amyloidosis Session from VJHemOnc

The most common form of amyloidosis, light-chain (AL) amyloidosis, results from abnormalities in plasma cells causing them to produce abnormal…

Date: 13th April 2021

The Post-EBMT VJSessions from VJHemOnc

The 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) was held virtually this year and…

Date: 7th April 2021

Post-EBMT highlights in acute myeloid leukemia

Acute myeloid leukemia (AML) is the most common type of adult leukemia, with over 19,500 new cases estimated to be…

Date: 6th April 2021

The CLL Sessions: highlights from ASH 2020

Chronic lymphocytic leukemia (CLL), also known as B-cell CLL (B-CLL) is the most common leukemia in Europe and North America….

Date: 17th March 2021

The Lymphoma Sessions: highlights from ASH 2020

Lymphoma is a collection of cancers which develop in the lymphatic system and affect the lymphocytes. The risk factors for…

Date: 17th March 2021

The MDS Sessions: Giants in MDS

The diagnosis and treatment of myelodysplastic syndromes (MDS) has moved on dramatically in the few three decades. From across the…

Date: 17th March 2021

Latest therapies in AML: IMGN632, magrolimab & gilteritinib

The armamentarium of therapeutic modalities in acute myeloid leukemia (AML) has taken several strides in the last few years as…

Date: 16th March 2021

VJSession: EBMT/EHA CAR-T Nursing Session

The 3rd European CAR T-cell Meeting, organized by the European Society for Blood and Marrow Transplantation (EBMT), and the European…

Date: 23rd February 2021

The Myeloma Sessions: key updates from ASH 2020

Over the last decades, a deeper understanding of multiple myeloma’s complex pathobiology has transformed the diagnosis, prognosis, and treatment paradigm,…

Date: 22nd February 2021

The MPN Sessions: Rapidly advancing genomic discoveries and treatment strategies in MPNs

Mechanistically, myeloproliferative neoplasms (MPNs), comprising primary myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), were a mystery for many…

Date: 19th February 2021

Updates for the management of MDS from ASH 2020

During the 62nd American Society of Hematology (ASH) 2020 Annual Meeting and Exposition, several abstracts provided important updates for the…

Date: 16th February 2021

The AML Sessions: highlights from ASH 2020

Improved understanding around the pathophysiology and heterogeneity of acute myeloid leukemia (AML) has led to a rapidly evolving treatment paradigm…

Date: 16th February 2021

The MDS Sessions: treating MDS around the world

The epidemiology, diagnosis and treatment of myelodysplastic syndromes (MDS) varies across the globe. In resource-limited countries, the diagnosis of MDS…

Date: 12th February 2021

Advances in the amyloidosis space: Prognostic factors, CAEL-101 immunotherapy and real-world data

Amyloidosis is the name attributed to a group of diseases caused by the extracellular accumulation of amyloid, an abnormal, insoluble…

Date: 5th February 2021

Developments in CLL: MRD, LOXO-305 and venetoclax at ASH 2020

Chronic Lymphocytic Leukemia (CLL) is a B-cell malignancy, predominantly affecting the elderly, which is characterized by an accumulation of immunologically…

Date: 28th January 2021

Myeloma at ASH 2020: talquetemab, CARTITUDE-1 & highlights

The field of multiple myeloma is rapidly evolving and can be credited to an increased understanding of the biology of…

Date: 20th January 2021

Advances in CAR T-cell therapies for lymphoma from ASH 2020

Lymphoma is a group of malignant neoplasms of lymphocytes that progress in the lymphatic system. Generally, lymphomas are categorized into…

Date: 18th January 2021

Moving forward in MPN: timing driver mutations and novel therapies from ASH 2020

Myeloproliferative neoplasms (MPNs) are a heterogeneous group of rare myeloid neoplasms characterized by the abnormal proliferation of hematopoietic stem cells…

Date: 11th January 2021

The MDS sessions: lower-risk disease

Myelodysplastic syndromes (MDS) represent a range of disorders characterized by morphologic dysplasia, cytopenias, and a risk of progression to acute…

Date: 7th December 2020

The AML Sessions: FLT3-mutated disease

Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are seen in 30% of all acute myeloid leukemia (AML) cases,…

Date: 27th November 2020

The Lymphoma Sessions: highlights from iwNHL 2020

This year’s virtual International Workshop on Non-Hodgkin Lymphoma (iwNHL) highlighted key progress in our understanding of various non-Hodgkin lymphoma (NHL)…

Date: 18th November 2020

The MDS sessions: clinical trial participation, endpoints & approvals

Myelodysplastic syndromes (MDS) represent a range of disorders characterized by morphologic dysplasia, cytopenias, and a risk of progression to acute…

Date: 17th November 2020

The AML Sessions: Venetoclax-based regimens

The BCL-2 inhibitor venetoclax has been evaluated in many hematological malignancies, including acute myeloid leukemia (AML). More recently, emerging mechanisms…

Date: 12th November 2020

The AML Sessions: IDH inhibitors

IDH mutations are present in 20% of acute myeloid leukemia (AML) patients and the use of IDH-targeting agents has shown…

Date: 3rd November 2020

The AML Sessions: Immunotherapy

Acute myeloid leukemia (AML) has seen rapid progression in the field of immuno-oncology which has led to vast improvements in…

Date: 8th October 2020

Advances in CAR-T and cellular therapy from EBMT 2020: MSCs, clinical trial updates and gene-edited effector cells

Cell therapy involves the transplantation of viable cells into a patient in order to trigger a medicinal effect. CAR-T is…

Date: 1st October 2020

SOHO 2020: Next questions in hematological malignancies

The Society of Hematologic Oncology (SOHO) 2020 Virtual Annual Meeting brought together global leading experts in hematological oncology who updated…

Date: 25th September 2020

The MPN Sessions: pathobiology, therapeutic strategies & clinical trials

Myeloproliferative neoplasms (MPNs) are a group of hematopoietic stem cell diseases characterized by the excessive production of one or more…

Date: 15th September 2020

Latest AML therapies: novel preparations and first in class agents

Acute myeloid leukemia (AML) is the most common type of acute leukemia among adults with almost 20,000 new cases reported…

Date: 14th September 2020

Advances in the lymphoma space: targeted therapies, PET-guided omission of RT and CAR T-cells

Lymphoma encompasses a wide selection of cancers that progress in the lymphatic system. Broadly, two types of lymphoma exist, non-Hodgkin…

Date: 10th September 2020

CLL: MRD and first-in class agents

Chronic lymphocytic leukemia (CLL) is a disorder characterized by morphologically mature but immunologically less mature lymphocytes, which accumulate in the…

Date: 13th August 2020

The Myeloma Sessions: Evolving management of myeloma & COVID-19

Patients with cancer frequently exhibit poorer post-COVID-19 infection outcomes, therefore the management of patients with hematological malignancies remains of high…

Date: 6th August 2020

MPNs highlights at EHA 2020: clinical trials, novel therapies & pitfalls

It is an exciting time in terms of therapeutic progress for myeloproliferative neoplasms (MPN). In recent years, there have been…

Date: 6th August 2020

The CLL Sessions: frontline therapy, BTK inhibitors, MRD negativity & novel therapies

A remarkable increase in the understanding of the pathogenesis of chronic lymphocytic leukemia (CLL) has led to the development of…

Date: 31st July 2020

The HemOnc & COVID-19 Sessions: treating hematological malignancies, reducing nosocomial COVID-19 infections, clinical trial participation and resource allocation

The ongoing COVID-19 pandemic caused by SARS-CoV-2 is an international public health issue and patients with cancer consistently demonstrate poorer…

Date: 28th July 2020

The AML Sessions: emerging immunotherapies, venetoclax-based regimens and targeted therapies in AML

The acute myeloid leukemia (AML) field has witnessed rapid evolution of late, with exciting developments in strategies for the treatment…

Date: 16th July 2020

Key updates in ALL at EHA 2020

Acute lymphoblastic leukemia (ALL) is a malignant disorder of lymphoid progenitor cells affecting both adults and children. With a greater…

Date: 7th July 2020

The Myeloma Sessions: smoldering myeloma, MRD evaluation, R/R disease & transplant-eligible patients

The multiple myeloma field is rapidly evolving, with exciting developments in strategies for the treatment of smoldering myeloma, relapsed/refractory (R/R)…

Date: 3rd July 2020

Systemic mastocytosis: current landscape, novel agents and COVID-19

Systemic mastocytosis (SM) is a rare hematological neoplasm. Advanced systemic mastocytosis can be sub-classified into either aggressive SM, SM with…

Date: 2nd June 2020

MRD assessment in AML: incorporation into clinical practice

Assessment of treatment efficacy in acute myeloid leukemia (AML) is highly relevant for further treatment stratification. In clinical trials, measurable…

Date: 22nd April 2020

Myeloma management in the COVID-19 era

The management of multiple myeloma presents many clinical challenges. The additional layer of complication COVID-19 places on patients and clinicians…

Date: 14th April 2020

CAR-T in the CLL space

Novel combinations work well for many patients suffering from chronic lymphocytic leukemia (CLL), but there is a subset of patients…

Date: 2nd April 2020

CAR T-cell therapy & multiple myeloma: past, present & future

CAR-T cell therapy offers a potentially paradigm-changing new treatment for multiple myeloma. Additionally, CAR-T toxicity is may be more manageable…

Date: 2nd April 2020

Harnessing the tumor microenvironment in lymphoma therapy

A deeper understanding of the characteristics, features and interactions at play in the tumor microenvironment has given great insight into…

Date: 2nd April 2020

CLL therapy: the latest trial updates and innovative novel therapies for the future

Recent clinical trials studying novel therapeutic strategies to target chronic lymphocytic leukemia (CLL) have brought a spotlight to their potential…

Date: 20th September 2019

Precision epigenetic therapy for B-cell lymphoma

Despite marked progress in the lymphoma treatment landscape, the prognosis of patients with relapsed and/or refractory disease remains poor; thus,…

Date: 18th July 2019

Induction therapy in myeloma: an ever-changing paradigm

In the majority of hematologic malignancies, induction treatment is given to achieve complete remission. In multiple myeloma, this has only…

Date: 18th July 2019

iwAL 2019: looking to the future of acute leukemia therapy

The treatment landscape of acute myeloid and lymphoblastic leukemia continues to evolve with the addition of novel therapies and methods…

Date: 6th June 2019

Acute leukemia: pushing boundaries in disease management

This is an exciting time in the acute leukemia field, with advances in both the treatment landscape and the pathology…

Date: 6th June 2019

CAR T-cell therapy and precision medicine in non-Hodgkin lymphoma

Precision medicine provides an array of benefits for the treatment of non-Hodgkin lymphoma patients, but it also has its challenges….

Date: 18th December 2018

MRD testing in multiple myeloma: new technology with promising clinical applications

Determining measurable residual disease (MRD) status is undoubtedly proving to be an effective method of prognostication and measurement of response…

Date: 23rd November 2018

CAR T-cells in myeloma: exploratory targets, payment models & treatment sequence

CAR T-cell therapy presents the opportunity to completely revolutionize the treatment of multiple myeloma, with research currently exploring the optimal…

Date: 11th October 2018

Patient discussion at EHA 2018: CAR T-cells and MRD in CLL

CAR T-cells have demonstrated impressive efficacy in a variety of hematological malignancies, but their use in chronic lymphocytic leukemia (CLL)…

Date: 14th September 2018

CLL therapies today: novel agents, combinations & the future of the field

Chronic lymphocytic leukemia (CLL) is experiencing a revolution in its treatment approaches. New therapies are constantly in development, and the…

Date: 20th August 2018

CAR T-cell therapy: where are we now and what’s in store for the future?

Over the last several years, CAR T-cell therapy has emerged as a revolution in immunotherapy, with incredible results to date….

Date: 25th July 2018

Focus on MRD: current landscape and future questions in hemonc

Measurable residual disease (MRD) has been a hot topic of interest due to its potential applications in the clinical setting….

Date: 4th July 2018

Acute leukemias discussion: what does genomics and epigenomics tell us about patient management?

A stimulating session on the implications of genomic data for the management of acute myeloid leukemia (AML) and acute lymphoblastic…

Date: 16th March 2018

Acute leukemias: is MRD already a surrogate for survival?

The use of minimal residual disease (MRD) in the management of acute leukemias is a hotly debated topic. Despite the…

Date: 9th March 2018

Revolutionary immunotherapies for lymphoma

Immunotherapy has emerged in recent years as an effective novel treatment for lymphoma, with studies constantly striving to identify new…

Date: 2nd February 2018

Latest advances and current challenges in immunotherapies for lymphoma

In this lively discussion, Catherine Bollard, MBChB, MD, FRACP, FRCPA, from the Children’s National Health System and George Washington University,…

Date: 15th December 2017

The circle of CLL: from gene discovery to targeted treatment

In this exciting feature, Carlo Croce, MD, from Ohio State University, Columbus, OH, provides an overview of the history of…

Date: 8th December 2017

Myeloma 2017 day 2 highlights: MRD, targeted therapies and imaging advances

This is a very exciting time for multiple myeloma (MM) research, with advances in a range of areas from new…

Date: 16th November 2017

Myeloma 2017 day 1 highlights: immunotherapy advances, a new MM subtype and liquid biopsies

Fantastic advances in immunotherapy, including CAR T-cells, bispecific antibodies and potential immunotherapy combinations, were presented at the Myeloma 2017 meeting…

Date: 16th November 2017

Debate on the use of MRD for multiple myeloma management

The highly anticipated panel discussion on the hot topic of MRD at the Myeloma 2017 meeting in Edinburgh, UK produced…

Date: 16th November 2017

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter